Epidermal growth factor receptor (EGFR)-activating mutations in non-small-cell lung cancer (NSCLC) are an important predictor of treatment efficacy with EGFR tyrosine kinase inhibitors (TKIs). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.